ArticleCancer research2019
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 96 citations in OpenAlex.
- [Clinicopathological Characteristics of ROS1-positive Non-small Cell Lung Cancer Based on Next-generation Sequencing].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Article
- Structural insights into the activation of the chicken ROS1 receptor by the NEL/NICOL ligand complex.Nature communications · 2026Article
- Optogenetic Translocation to Subcellular Compartments through Regulation of Protein Avidity.ACS synthetic biology · 2026Article
- Review
- The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients.Molecular oncology · 2025Article
- ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection.Histopathology · 2025Article
- Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations.Molecular cancer therapeutics · 2025Article
- Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates.Cancer metastasis reviews · 2025Review
- Visceral crisis in a patient with non-small cell lung cancer andTranslational lung cancer research · 2025Article
- Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions.Cancer · 2025Review
- Liquid-liquid phase separation: an emerging perspective on the tumorigenesis, progression, and treatment of tumors.Frontiers in immunology · 2025Review
- Recent Advancements in Subcellular Proteomics: Growing Impact of Organellar Protein Niches on the Understanding of Cell Biology.Journal of proteome research · 2024Review
- Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.Cancer medicine · 2024Review
- CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.Journal of translational medicine · 2024Article
- Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2.Cell chemical biology · 2024Article
- ZDHHC5-mediated S-palmitoylation of FAK promotes its membrane localization and epithelial-mesenchymal transition in glioma.Cell communication and signaling : CCS · 2024Article
- Transcriptomic analysis ofFrontiers in oncology · 2024Article
- KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT Pathway.Cancers · 2023Article
- Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Analysis of CD74 Occurrence in Oncogenic Fusion Proteins.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Dana S NeelDepartment of Medicine, University of California at San Francisco, San Francisco, California.
David V AllegakoenDepartment of Medicine, University of California at San Francisco, San Francisco, California.ORCID 0000-0002-0261-2962
Victor OlivasDepartment of Medicine, University of California at San Francisco, San Francisco, California.
Manasi K MayekarDepartment of Medicine, University of California at San Francisco, San Francisco, California.
Golzar HemmatiDepartment of Medicine, University of California at San Francisco, San Francisco, California.
Nilanjana ChatterjeeDepartment of Medicine, University of California at San Francisco, San Francisco, California.
Collin M BlakelyDepartment of Medicine, University of California at San Francisco, San Francisco, California.
Caroline E McCoachDepartment of Medicine, University of California at San Francisco, San Francisco, California.
Julia K RotowDepartment of Medicine, University of California at San Francisco, San Francisco, California.
Anh LeDepartment of Medicine, University of Colorado Anschutz Medical Campus, Denver, Colorado.
Niki KarachaliouCancer Biology and Precision Medicine Program Catalan Institute of Oncology Hospital Germans Trias i Pujol Badalona, Barcelona, Spain.
Rafael RosellCancer Biology and Precision Medicine Program Catalan Institute of Oncology Hospital Germans Trias i Pujol Badalona, Barcelona, Spain.
Jonathan W RiessUniversity of California Davis School of Medicine, Sacramento, California.
Robert NicholsRevolution Medicines, Redwood City, California.
Robert C DoebeleDepartment of Medicine, University of Colorado Anschutz Medical Campus, Denver, Colorado.ORCID 0000-0001-6728-6857
Trever G BivonaDepartment of Medicine, University of California at San Francisco, San Francisco, California. trever.bivona@ucsf.edu.
University of California, San Francisco · USInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESUniversity of Colorado Anschutz Medical Campus · USPancreatic Cancer Action Network · USRevolution Medicines (United States) · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6MUCSF Project 1U54CA224081 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona, Jack Roth · 2017 to 2026
$12.9MMolecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4MThe Cancer Target Discovery and Development Network at UCSFU01CA217882 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANDYOPADHYAY, SOURAV, BIVONA, TREVER G · 2017 to 2021
$5.2MCharacterization of YAP as a rational companion target in lung cancerR01CA204302 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona · 2017 to 2026
$3.7MRational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer TreatmentR01CA169338 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2013 to 2023
$3.4MDiscovery of Rational Companion Therapeutic Targets to Optimize Cancer TreatmentDP2CA174497 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2012 to 2012
$2.3MOptimizing biologically-based rational polytherapy in ALK+ lung cancerR01CA211052 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2017 to 2021
$1.8MDissecting the function of PI3K/mTOR pathway activation in ROS1 fusion-mediated oncogenesis and resistance to targeted therapyF30CA210444 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NEEL, DANA SARABETH · 2016 to 2019
$171kDoris Duke Charitable Foundation 2018110NCI NIH HHS DP2 CA174497NCI NIH HHS F30 CA210444NCI NIH HHS R01 CA169338NCI NIH HHS R01 CA204302NCI NIH HHS R01 CA211052NCI NIH HHS T32 CA108462NCI NIH HHS U01 CA217882NCI NIH HHS U54 CA224081NIGMS NIH HHS T32 GM007618
Abstract
Chromosomal rearrangements involving receptor tyrosine kinases (RTK) are a clinically relevant oncogenic mechanism in human cancers. These chimeric oncoproteins often contain the C-terminal kinase domain of the RTK joined
Indexed as
Adenocarcinoma of LungAnimalsAntigens, CDbeta-D-Galactoside alpha 2-6-SialyltransferaseEndosomesHEK293 CellsHumansLung NeoplasmsMAP Kinase Signaling SystemMiceMice, Inbred NODMice, SCIDNIH 3T3 CellsOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene ProteinsAntigens, CDbeta-D-Galactoside alpha 2-6-SialyltransferaseOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene Proteinsras ProteinsROS1 protein, humanSDC4 protein, humanSialyltransferasesSLC34A2 protein, humanSodium-Phosphate Cotransporter Proteins, Type IIbST6GAL1 protein, humanSyndecan-4
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.